Loading...
Loading chart...



The current price of TRML is 0 USD — it has increased 0 % in the last trading day.
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is pacibekitug (TOUR006), a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is focused on two strategic paths for TOUR006, the first of which is cardiovascular inflammation. Its second strategic path is thyroid eye disease (TED). TED is an autoimmune disease characterized by autoantibody-mediated activation of the tissues surrounding the eye, causing inflammation and disfigurement which can be sight-threatening in severe cases.
Wall Street analysts forecast TRML stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRML is47.93 USD with a low forecast of 47.50 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Tourmaline Bio Inc revenue for the last quarter amounts to -25.97M USD, increased 18.22 % YoY.
Tourmaline Bio Inc. EPS for the last quarter amounts to -20271000.00 USD, increased 12.57 % YoY.
Tourmaline Bio Inc (TRML) has 74 emplpoyees as of February 09 2026.
Today TRML has the market capitalization of 0.00 USD.